Voyager Therapeutics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a price target of $22.
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics' stock price increased following Guggenheim's initiation of coverage with a Buy rating and a $22 price target.

March 26, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Voyager Therapeutics' stock price is likely to experience a short-term increase following Guggenheim's positive coverage initiation.
Analyst ratings, especially from reputable firms like Guggenheim, can significantly influence investor sentiment and stock prices. The initiation of coverage with a Buy rating and a high price target suggests a strong bullish outlook for Voyager Therapeutics, likely leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100